Retatrutide dose escalation in the published trials

Post #26 is the version of this I will quote in future. One addition.

The hepatic-steatosis rationale follows directly from glucagon receptor agonism promoting fat oxidation in the liver. Mechanistic plausibility in this field has a poor record of predicting clinical outcomes, which is why the trials matter more than the mechanism.

No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.

How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does not establish safety, durability, or whether real humans differ from the selected population.

I keep a log of this specifically because memory is unreliable about it.

Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.

That is all the detail I have. Someone else will have more.

Dose-response in the phase 2 obesity work was clear across the studied range, with no obvious plateau within it. Extrapolating beyond the highest studied dose from that is exactly the reasoning trials are designed to prevent.

This has been discussed before and I could not find the thread, so, again.

Taking post #71 at face value and following it one step further.

Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase 2 trial without a dual-agonist comparator arm cannot distinguish the two.

Where I would look next, rather than where I would stop.

Adding the boring version of retatrutide dose escalation, because the interesting version keeps getting posted and the boring one is usually right.

Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.

Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.

The part I am sure of is shorter than the part I have written.

I had written a reply contradicting post #127 and deleted it. Here is what survived.

On analysis: a chromatographic purity figure for an investigational compound is harder to interpret than for a well-characterised one, because there is no reference standard in wide circulation and no published impurity profile to compare against.

The disagreement above is smaller than it looks once the terms are fixed.